Apolipoprotien E (apoE) polymorphism is a human genetic risk factor and has been well-established to be associated with Alzheimer’s disease, lipid abnormalities, and cardiovascular disease (CVD). ApoE gene polymorphism is re- ported to correlate with lipid metabolism disturbances and coronary artery stenosis. Furthermore, ε4 allele carriers were found to have poor prognosis in survival rates of post-myocardial infarction. The purpose of the review is to distinguish the possible of apoE gene polymorphism as a determinant for CVD and its association. Preliminary data suggest ε4 allele carrier identification could be beneficial for risk stratification of CVD and initiation of statin therapy as primary intervention. Numerous studies have been done, however, results varied between studies as well as in different population. The evidence presented herein can help describe the risk prediction based on apoE gene poly- morphism.